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Abstract 
Reduction in visual acuity due to orbital metastasis is rarely the first sign of lung cancer 
and very few cases have been published in the literature. Here we report a rare case of 
lung adenocarcinoma with orbital metastasis as the first presenting sign. The incidence 
of primary tumors that metastasize to the orbit is approximately 7%. In 19% of the cases, 
there is no history of cancer when the patient presents with ophthalmic symptoms, and 
in 10%, the primary site remains obscure despite intensive systemic evaluation. Our 
patient showed a partial improvement in vision after successful combination of 
chemotherapy and radiotherapy. Blurred vision due to orbital metastasis as the primary 
symptom of lung cancer is very uncommon. A great index of suspicion is essential when 
an orbital lesion appears. 
 
Case Presentation 
A 38-year-old Caucasian woman, who was a heavy smoker, was referred to the ophthalmology clinic 
with reduced vision, blurred and double vision, persistent pain in the right frontal-parietal region, and 
increased pressure on the right orbit for the past 2 months. She had no nausea, weight loss, vomiting, or 
respiratory symptoms. She had no family history of malignant diseases and no previous medical history. 
After physical examination, showing visual acuity of 3/20 in the right eye, a normal left eye and no 
findings from fundus examination, the patient underwent an orbital computed tomography 
demonstrating a right solid tissue orbital mass, measuring 11 × 10 × 7 mm, invading the posterior sclera 
and pressing on the optic nerve (fig. 1). A fine-needle orbital biopsy aspiration revealed a low 
differentiated adenocarcinoma. Subsequent chest computed tomography showed an irregularly shaped 
pulmonary mass measuring 2 × 1.5 cm in the apical section of the right inferior lobe, without lymph 
node involvement (fig. 2). A specimen of the lesion taken via incision biopsy confirmed the diagnosis of 
a low-grade lung adenocarcinoma.  
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The patient was therefore diagnosed with metastatic lung adenocarcinoma (T1, N0, M1, stage IV), 
and was treated with combination chemotherapy consisting of docetaxel 100 mg/m
2 plus carboplatin 
(AUC = 5.5) on day 1 and bevacizumab (7.5 mg/kg repeated every 28 days for 6 cycles) with no 
improvement of visual acuity and stable lung disease. After the completion of the 6th cycle, 
bevacizumab was continued as maintenance therapy every 21 days for 9 cycles. Palliative radiotherapy at 
the orbital mass (external beam 3D conformal radiotherapy, using linear accelerator, with a total dose of 
30 Gy) was added during maintenance therapy. A new thoracic computed tomography at the 9th 
maintenance cycle showed progressive disease with aggravation of the initial lung mass, a right 
pulmonary effusion and 3 additional lung lesions in the right lower lobe and left axillary lymph nodes 
enlargement. Second-line chemotherapy was initiated with gemcitabine (1,250/m
2 body surface area, 
days 1 and 8) and pemetrexed (500 mg/m
2, day1), plus bevacizumab at the maintenance dose every 21 
days for 4 cycles resulting in lung tumor reduction (from 2 to 1.4 cm at the longest diameter). Serial 
magnetic resonance imaging scans of the head performed after the completion of the second-line 
chemotherapy revealed partial resolution of the orbital mass and improvement of vision from 0/10 to 
2/10 (fig. 3). 
It is well known that in non-small cell lung cancer adenocarcinoma epidermal growth factor 
receptor (EGFR) mutations could be isolated, and tyrosine kinase inhibitors (TKIs) such as Tarceva-
erlotinib or Iressa-gefinitib could be given as therapy [1–3]. The histopathology report from our biopsy 
was negative for EGFR mutations. TKIs are an established second-line treatment for EGFR positive 
mutation adenocarcinoma, although there is a debate whether these 2 TKI’s are equally efficient [4]. 
A sign of response to this treatment is the rush that occurs in the patient. It seems that positive 
response correlates with the intensity of the presented rush. First-line treatment with TKIs failed to be 
established. Nevertheless, a subgroup of treatment-naive patients could benefit from first-line treatment 
directly with TKIs instead of the commonly used doublets (platinum plus second agent) [5]. 
Discussion 
Metastatic tumor is considered the most common intra-ocular malignancy, but many 
eye metastases go unrecognized. The most common site of ocular metastases is the highly 
vascular uveal tract (choroid, iris and ciliary body) – and especially the posterior portion 
of the choroids – with a proportion of 7:1 in relation to metastasis affecting the posterior 
segment of the eye, the orbit and the optic nerve [6–10]. Published reports indicate breast 
and lung tumors to be the commonest primary neoplasms leading to eye metastasis and 
metastases to the eye or orbit develop in approximately 0.7 to 12% of patients with lung 
cancer [6, 7, 11–14]. In our patient, the ocular symptoms were probably due to the 
compression of the optic nerve or shift of the eye forwards (proptosis) leading to corneal 
exposure damage. In our case, no extreme forward shift of the eye was observed. 
Most ocular metastases are asymptomatic and this may also explain the low incidence 
observed [15, 16]. Therefore, blurred vision or change in visual acuity as the initial 
manifestation of lung carcinoma is very rare. Another interesting finding is the timing of 
ocular involvement. Ocular manifestations of systemic malignancy may precede the 
diagnosis of cancer. Approximately 30% of the patients with orbital metastases have no 
history of primary cancer at the time that the ocular metastasis is detected [17]. These 
findings indicate that symptomatic ocular metastasis could be an early event [6, 7]. 
However, occurrences of metastatic lesions in the eye suggest hematogenous spread of 
cancer, so the lesions are considered preterminal events that occur at the final stage of 
lung carcinoma, when the majority of the patients already suffers from the typical lung 
cancer symptoms, and the mean survival is not expected to be more than 5 to 6 months 
[18, 19]. The major determinants of survival after the diagnosis of choroidal metastasis 
are primary tumor type and local tumor invasion at the time of diagnosis.  
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Available treatment options of orbital metastasis are external beam radiotherapy, 
plaque radiotherapy, and newer methods like surgical resection, transpupillary 
thermotherapy and intravitreal chemotherapy. Systemic chemotherapy alone can also be 
used to treat metastatic tumors to the eye and orbit [20]. However, chemotherapy of the 
primary cancer alone is not recommended in this case. Additionally, anti-vascular 
endothelial growth factor therapy can be used to slow the progress of maculopathy and 
neuropathy as well as spare vision after local radiotherapy [21–23]. 
Conclusions 
In conclusion, when an orbital lesion is discovered, the differential diagnosis should 
include secondary metastases due to malignant tumors originated from distal organs. 
This case highlights that the ocular base is a potential site of metastasis of lung cancer and 
the clinical doctor should be alert. 
 
 
 
 
 
 
Fig. 1. CT brain scan upon admission. 
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Fig. 2. CT thorax scan upon admission. 
 
 
 
Fig. 3. Brain MRI after completion of 2nd line chemotherapy. 
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